Subcutaneous Daratumumab “Potential Game Changer” for Multiple Myeloma

ATLANTA—Subcutaneous administration of the anti-CD 38 monoclonal antibody daratumumab could help more patients get this emerging therapy more easily for their advanced or recently-diagnosed multiple myeloma according to research reported from the Pavo study at the 2017 American Society of Hematology annual meeting.

Study author Ajai Chari MD, Associate Professor of Medicine and Director of Clinical Research in the Multiple Myeloma Program, at Mount Sinai Hospital in New York tells the Audio Journal of Oncology “These are really exciting results. This would be extremely practice changing. Daratumumab has moved from monotherapy in advanced disease to first relapse. And now—at this year’s ASH—we have newly diagnosed [myeloma]. That’s a lot of dara[tumumab] being used globally. And to be giving a more convenient, potentially safer, form of administration is really going to be very practice changing.”

Abstract 838: Subcutaneous Delivery of Daratumumab in Patients (pts) with Relapsed or Refractory Multiple Myeloma (RRMM): Pavo, an Open-Label, Multicenter, Dose Escalation Phase 1b Study

READ MORE about the Pavo study in Oncology Times